<PAGE>
                                                                    EXHIBIT 99.1

                                                           FOR IMMEDIATE RELEASE


                  [ADVANCED NEUROMODULATION SYSTEMS LETTERHEAD]


                        ADVANCED NEUROMODULATION SYSTEMS
                     COMPLETES MICRONET MEDICAL ACQUISITION


         DALLAS, TEXAS, November 26, 2002 -- ADVANCED NEUROMODULATION SYSTEMS,
INC. (ANS) (NASDAQ:ANSI) announced today that it has completed its previously
announced acquisition of MICRONET MEDICAL, INC. (MICRONET), a developer of
medical devices based on proprietary micro-lead technology.

         Under the terms of the transaction, which was structured as a merger,
ANS acquired only Micronet's proprietary technology and certain associated
tangible assets. Micronet's OEM and sterilization operations, other tangible
assets, certain liabilities and certain employees have become part of a separate
unaffiliated company. The unaffiliated company will continue to serve Micronet's
OEM and sterilization customers without interruption. ANS assumed no material
debt, liabilities, or overhead in the transaction.

         To acquire Micronet, ANS paid the Micronet shareholders $500,000 in
cash and 156,302 shares of ANS Common Stock with a value of $5,233,000, based on
the average trading price for the 30 days preceding closing. In addition, if
certain product, regulatory approval and sales milestones are met, ANS could pay
the former Micronet shareholders an additional number of shares of Common Stock
with an aggregate value of up to $9,000,000. Important milestone deadlines occur
six, twelve and eighteen months following the closing for product milestone
purposes, while other milestones depend on the receipt of regulatory approvals
and meeting an aggregate sales milestone. All milestones must be met within the
next four to five years, depending on the milestone.

ABOUT ADVANCED NEUROMODULATION SYSTEMS

         Advanced Neuromodulation Systems designs, develops, manufactures and
markets implantable systems used to manage chronic intractable pain and other
disorders of the central nervous system. Forbes magazine recently recognized ANS
as one of America's 200 Best Small Companies. Additional information is
available at www.ans-medical.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995:


<PAGE>


         Statements contained in this press release that are not based on
historical facts are "forward-looking statements." Terms such as "plan,"
"should," "would," "anticipate," "believe," "intend," "estimate," "expect,"
"predict," and similar expressions are intended to identify forward-looking
statements. Such statements are by nature subject to uncertainties and risks,
including but not limited to: market acceptance of the Micronet lead; completion
of new products in an efficient and timely manner; obtaining regulatory
approvals on a timely and cost-efficient basis; the satisfactory completion of
clinical trials and/or market tests; the adequacy, acceptability and timeliness
of component supply; the accounting determination of the value of the intangible
assets acquired, the resolution of other accounting matters and the resulting
impact on financial statement presentation; reimbursement; competition; and
other risks detailed from time to time in the Company's SEC filings.
Consequently, if such management assumptions prove to be incorrect or such risks
or uncertainties materialize, anticipated results could differ materially from
those forecast in forward-looking statements.


